diazoxide has been researched along with Autoimmune Diabetes in 20 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Individuals with long-standing type 1 diabetes (T1D) are at increased risk of severe hypoglycemia secondary to impairments in normal glucose counterregulatory responses (CRRs)." | 6.80 | Diazoxide improves hormonal counterregulatory responses to acute hypoglycemia in long-standing type 1 diabetes. ( George, PS; McCrimmon, RJ; Palmer, CN; Tavendale, R, 2015) |
| "Right atrial sections from four patient groups-non-diabetic, insulin-dependent diabetes mellitus (IDDM), non-insulin-dependent diabetes mellitus (NIDDM) receiving glibenclamide, and NIDDM receiving metformin-were subjected to one of the following protocols: aerobic control, simulated ischemia/reoxygenation, ischemic preconditioning before ischemia, and pharmacological preconditioning with alpha 1 agonist phenylephrine, adenosine, the mito-K(ATP) channel opener diazoxide, the protein kinase C (PKC) activator phorbol-12-myristate-13-acetate (PMA), or the p38 mitogen-activated protein kinase (p38MAPK) activator anisomycin." | 3.73 | Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. ( Fowler, A; Galiñanes, M; Hassouna, A; Loubani, M; Matata, BM; Standen, NB, 2006) |
| "Individuals with long-standing type 1 diabetes (T1D) are at increased risk of severe hypoglycemia secondary to impairments in normal glucose counterregulatory responses (CRRs)." | 2.80 | Diazoxide improves hormonal counterregulatory responses to acute hypoglycemia in long-standing type 1 diabetes. ( George, PS; McCrimmon, RJ; Palmer, CN; Tavendale, R, 2015) |
| "Diazoxide treatment reduced A1C from 8." | 2.75 | Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta}-cell function and autoimmunity but improves glycemic control. ( Dørflinger, GH; Grill, V; Hals, I; Kollind, M; Moen, T; Nermoen, I; Radtke, MA; Skeie, S; Svartberg, J; Sørheim, JI, 2010) |
| "Diazoxide was given to six patients during a 7-day period (100 mg three times daily), followed by a 3-week washout." | 2.69 | Induction of beta-cell rest in type 1 diabetes. Studies on the effects of octreotide and diazoxide. ( Berne, C; Björk, E; Karlsson, FA, 1998) |
| "Type 1 diabetes is the result of a chronic inflammatory process that causes elimination of insulin-producing beta-cells, resulting in insulin deficiency and hyperglycemia." | 2.41 | Beta-cell activity and destruction in type 1 diabetes. ( Berne, C; Björk, E; Karlsson, FA; Kullin, M; Li, Z; Ma, JY; Schölin, A; Zhao, L, 2000) |
| "Diazoxide was commenced in 28 patients (82." | 1.72 | Clinical and genetic heterogeneity of HNF4A/HNF1A mutations in a multicentre paediatric cohort with hyperinsulinaemic hypoglycaemia. ( Brusgaard, K; Christesen, H; Conlon, N; Dastamani, A; Demirbilek, H; Flanagan, SE; Gubaeva, D; Houghton, JAL; McGlacken-Byrne, SM; Melikyan, M; Mohammad, JK; Murphy, NP; Schou, AJ; Shah, P; Siersbæk, J, 2022) |
| "Eight weeks after type 1 diabetes induction, DZ preconditioned, and non-preconditioned DM-EPCs were transplanted into left ventricle of diabetic rats (at a dose of 2 × 10(6) DM-EPCs/70 μl serum free medium)." | 1.42 | Diazoxide preconditioning of endothelial progenitor cells from streptozotocin-induced type 1 diabetic rats improves their ability to repair diabetic cardiomyopathy. ( Ali, M; Anjum, MS; Khan, SN; Mehmood, A; Riazuddin, S; Tarrar, MN, 2015) |
| "Insulin-dependent diabetes mellitus (IDDM) is associated with the formation of autoantibodies against different antigens in the islets of Langerhans, so-called islet cell antibodies (ICA)." | 1.29 | Modulation of beta-cell activity and its influence on islet cell antibody (ICA) and islet cell surface antibody (ICSA) reactivity. ( Björk, E; Grawé, J; Hallberg, A; Kämpe, O; Karlsson, FA; Norheim, I, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| McGlacken-Byrne, SM | 1 |
| Mohammad, JK | 1 |
| Conlon, N | 1 |
| Gubaeva, D | 1 |
| Siersbæk, J | 1 |
| Schou, AJ | 1 |
| Demirbilek, H | 1 |
| Dastamani, A | 1 |
| Houghton, JAL | 1 |
| Brusgaard, K | 1 |
| Melikyan, M | 1 |
| Christesen, H | 1 |
| Flanagan, SE | 1 |
| Murphy, NP | 1 |
| Shah, P | 1 |
| Welters, A | 1 |
| Meissner, T | 2 |
| Grulich-Henn, J | 1 |
| Fröhlich-Reiterer, E | 1 |
| Warncke, K | 1 |
| Mohnike, K | 1 |
| Blankenstein, O | 1 |
| Menzel, U | 1 |
| Datz, N | 1 |
| Bollow, E | 1 |
| Holl, RW | 1 |
| George, PS | 1 |
| Tavendale, R | 1 |
| Palmer, CN | 1 |
| McCrimmon, RJ | 1 |
| Ali, M | 1 |
| Mehmood, A | 1 |
| Anjum, MS | 1 |
| Tarrar, MN | 1 |
| Khan, SN | 1 |
| Riazuddin, S | 1 |
| Grill, V | 2 |
| Radtke, M | 1 |
| Qvigstad, E | 1 |
| Kollind, M | 2 |
| Björklund, A | 1 |
| Radtke, MA | 1 |
| Nermoen, I | 1 |
| Skeie, S | 1 |
| Sørheim, JI | 1 |
| Svartberg, J | 1 |
| Hals, I | 1 |
| Moen, T | 1 |
| Dørflinger, GH | 1 |
| Chen, ZC | 1 |
| Cheng, YZ | 1 |
| Chen, LJ | 1 |
| Cheng, KC | 1 |
| Li, Y | 1 |
| Cheng, J | 1 |
| Wendel, U | 1 |
| Burgard, P | 1 |
| Schaetzle, S | 1 |
| Mayatepek, E | 1 |
| Ortqvist, E | 1 |
| Björk, E | 6 |
| Wallensteen, M | 1 |
| Ludvigsson, J | 1 |
| Aman, J | 1 |
| Johansson, C | 1 |
| Forsander, G | 1 |
| Lindgren, F | 1 |
| Berglund, L | 1 |
| Bengtsson, M | 1 |
| Berne, C | 4 |
| Persson, B | 1 |
| Karlsson, FA | 6 |
| Hassouna, A | 1 |
| Loubani, M | 1 |
| Matata, BM | 1 |
| Fowler, A | 1 |
| Standen, NB | 1 |
| Galiñanes, M | 1 |
| Kämpe, O | 2 |
| Grawé, J | 1 |
| Hallberg, A | 1 |
| Norheim, I | 1 |
| Williams, AJ | 1 |
| Beales, PE | 1 |
| Krug, J | 1 |
| Procaccini, E | 1 |
| Signore, A | 1 |
| Xu, S | 1 |
| Gale, EA | 1 |
| Pozzilli, P | 1 |
| Wibell, L | 1 |
| Oskarsson, P | 1 |
| Rasmussen, SB | 1 |
| Sørensen, TS | 1 |
| Hansen, JB | 1 |
| Mandrup-Poulsen, T | 1 |
| Hornum, L | 1 |
| Markholst, H | 1 |
| Kullin, M | 1 |
| Li, Z | 1 |
| Ma, JY | 1 |
| Schölin, A | 1 |
| Zhao, L | 1 |
| Gossain, VV | 1 |
| Werk, EE | 1 |
| Sholiton, LJ | 1 |
| Srivastava, L | 1 |
| Knowles, HC | 1 |
| Bleicher, SJ | 1 |
| Chowdhury, F | 1 |
| Podolsky, S | 1 |
| Fleishman, P | 1 |
| Goldner, MG | 1 |
| Söling, HD | 1 |
| Unger, KO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Diazoxide in Acute Hypoglycaemia[NCT01488136] | Phase 4 | 12 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for diazoxide and Autoimmune Diabetes
| Article | Year |
|---|---|
Beneficial effects of K-ATP channel openers in diabetes: an update on mechanisms and clinical experiences.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diazoxide; Humans; Hypoglycemic Agents; Insuli | 2009 |
Beta-cell rest: a strategy for the prevention of autoimmune diabetes.
Topics: Autoantibodies; Autoantigens; Diabetes Mellitus, Type 1; Diazoxide; Disease Progression; Gene Expres | 1997 |
Beta-cell activity and destruction in type 1 diabetes.
Topics: Animals; Autoantigens; Diabetes Mellitus, Type 1; Diazoxide; Humans; Islets of Langerhans; Mice; Oct | 2000 |
5 trials available for diazoxide and Autoimmune Diabetes
| Article | Year |
|---|---|
Diazoxide improves hormonal counterregulatory responses to acute hypoglycemia in long-standing type 1 diabetes.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 1; Diazoxide; Double-Blind Method; Female; Genotype; Huma | 2015 |
Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta}-cell function and autoimmunity but improves glycemic control.
Topics: Adult; Antihypertensive Agents; Autoimmunity; Blood Glucose; Body Weight; Circadian Rhythm; Diabetes | 2010 |
Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes.
Topics: Adolescent; C-Peptide; Child; Diabetes Mellitus, Type 1; Diazoxide; Female; Humans; Hypoglycemic Age | 2004 |
Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes.
Topics: Adult; Autoantibodies; C-Peptide; Diabetes Mellitus, Type 1; Diazoxide; Drug Therapy, Combination; F | 1996 |
Induction of beta-cell rest in type 1 diabetes. Studies on the effects of octreotide and diazoxide.
Topics: Adult; Antihypertensive Agents; Blood Glucose; C-Peptide; Data Interpretation, Statistical; Diabetes | 1998 |
12 other studies available for diazoxide and Autoimmune Diabetes
| Article | Year |
|---|---|
Clinical and genetic heterogeneity of HNF4A/HNF1A mutations in a multicentre paediatric cohort with hyperinsulinaemic hypoglycaemia.
Topics: Adolescent; Birth Weight; Child; Child, Preschool; Cohort Studies; Diabetes Mellitus, Type 1; Diabet | 2022 |
Characterization of diabetes following pancreatic surgery in patients with congenital hyperinsulinism.
Topics: Adolescent; Blood Glucose; C-Peptide; Child; Child, Preschool; Congenital Hyperinsulinism; Diabetes | 2018 |
Diazoxide preconditioning of endothelial progenitor cells from streptozotocin-induced type 1 diabetic rats improves their ability to repair diabetic cardiomyopathy.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers; Blood Glucose; Cell Proliferation; Ce | 2015 |
Increase of ATP-sensitive potassium (K(ATP)) channels in the heart of type-1 diabetic rats.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Animals; ATP-Binding Cassette Transporters; | 2012 |
Long-term follow-up of 114 patients with congenital hyperinsulinism.
Topics: Adolescent; Age of Onset; Child; Child, Preschool; Developmental Disabilities; Diabetes Mellitus, Ty | 2003 |
Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium.
Topics: Adenosine; Adrenergic alpha-Agonists; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitu | 2006 |
Modulation of beta-cell activity and its influence on islet cell antibody (ICA) and islet cell surface antibody (ICSA) reactivity.
Topics: Animals; Autoantibodies; Diabetes Mellitus, Type 1; Diazoxide; Flow Cytometry; Glipizide; Humans; Im | 1993 |
Tolbutamide reduces the incidence of diabetes mellitus, but not insulitis, in the non-obese-diabetic mouse.
Topics: Aging; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diazoxide; Female; Insulin; Islets of Lang | 1993 |
Functional rest through intensive treatment with insulin and potassium channel openers preserves residual beta-cell function and mass in acutely diabetic BB rats.
Topics: Animals; Arginine; Blood Glucose; C-Peptide; Cells, Cultured; Diabetes Mellitus, Type 1; Diazoxide; | 2000 |
Plasma renin activity in juvenile diabetes mellitus and effect of diazoxide.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diazoxid | 1975 |
Studies on diazoxide-induced hyperglycemia: an extrapancreatic mechanism.
Topics: Adenoma, Islet Cell; Adult; Aged; Blood Glucose; Child; Coloring Agents; Diabetes Mellitus; Diabetes | 1968 |
The role of insulin in the regulation of -amylase synthesis in the rat pancreas.
Topics: Adrenalectomy; Amino Sugars; Amylases; Animals; Anti-Bacterial Agents; Chymotrypsin; Dactinomycin; D | 1972 |